21026 ⎘
Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof; Enzymes; Proenzymes; Derivatives thereof Hydrolases (3)
Method to prevent cancer metastasis and inhibit inflammation by inhibition of p68 interaction with calmodulin
#302Anti-TNF antibody formulations
#303COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDER
#304Methods for Identifying Fragile Histidine Triad (FHIT) Interaction and Uses Thereof
#305USE OF HSP70 AS A REGULATOR OF ENZYMATIC ACTIVITY
#306Therapies for Disorders of the Cornea and Conjunctiva
#307Compositions and methods for regulating glucose metabolism
#308Proteomic IPF markers
#309Compounds for improved viral transduction
#310CRISPR-Cas systems and methods for altering expression of gene products
#311Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
#312Na/K-ATPase-derived peptide Src inhibitors and ouabain antagonists and uses thereof
#313Cosmetic treatment system and methods
#314Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
#315Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
#316Method of treating lysosomal storage diseases
#317Use of HSP70 as a regulator of enzymatic activity
#318Feed additive composition
#319EXTRACTS ISOLATED FROM ELECTROPORATED AMBHIBIAN OOCYTES AND USE THEREOF IN TREATING DISEASES AND DISORDERS
#320Method of treating lysosomal storage diseases using nucleases and a transgene
#321GASTRO-RESISTANT ENZYME PHARMACEUTICAL COMPOSITIONS
#322Mutants of L-asparaginase
#323METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY
#324Bacteriophage lysin and antibiotic combinations against gram positive bacteria
#325Treatment of Sanfilippo syndrome type B by intrathecal administration of alpha-n-acetylglucosaminidase
#326SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE
#327Mitochondrial targeted RNA expression system and use thereof
#328Enzyme combinations to reduce brain tissue swelling
#329Methods for increasing intracellular activity of Hsp70
#330COMPOSITIONS AND METHODS FOR SELECTIVELY PRODUCING SIRNA
#331Method for treating systemic bacterial, fungal and protozoan infection
#332ENZYMATIC PERACID GENERATION FOR USE IN SKIN CARE PRODUCTS
#333METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS
#334Protein formulations and methods of making same
#335Na+/K+-ATPase-specific peptide inhibitors/activators of Src and Src family kinases
#336Method and pharmacological composition for the diagnosis and treatment of male sub-fertility
#337BIOMARKERS FOR SANFILIPPO SYNDROME AND USES THEREOF
#338Degradation resistant HSP70 formulations and uses thereof
#339Use of caftaric acid and lactic bacterium in food supplement for regulating skin pigmentation
#340Compositions and combinations of organophosphorus bioscavengers and hyaluronan-degrading enzymes, and methods of use
#341Phenotypic reversion of pancreatic carcinoma cells
#342PRODUCTS AND METHODS FOR DELIVERY OF POLYNUCLEOTIDES BY ADENO-ASSOCIATED VIRUS FOR LYSOSOMAL STORAGE DISORDERS
#343Apyrase therapy for bleeding conditions
#344Methods of treating human papillomavirus
#345Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
#346ENZYMATIC PERACID GENERATION FOR USE IN HAIR CARE PRODUCTS
#347NON-AQUEOUS STABLE COMPOSITION FOR DELIVERING SUBSTRATES FOR A DEPILATORY PRODUCT USING PERACIDS
#348AQUEOUS STABLE COMPOSITION FOR DELIVERING SUBSTRATES FOR A DEPILATORY PRODUCT USING PERACETIC ACID
#349Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
#350Screening methods for compounds that modulate ARF-6 mediated endosomal redistribution
#351Treatment of Sensory Disturbance Disorders
#352Methods and materials for modulating deubiquitinases and ubiquitinated polypeptides
#353CONTROL OF BIOFILM FORMATION
#354Methods for identifying fragile histidine triad (FHIT) interaction and uses thereof
#355USE OF A DEAD-BOX RNA HELICASE FOR INDUCING CYTOKINE PRODUCTION
#356Oligosaccharide-protein conjugates
#357Compositions and methods for treating cancer
#358Use of Hsp70 as a regulator of enzymatic activity
#359SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE
#360Cosmetic Methods And Compositions For Repairing Human Skin
#361FOCAL CALCIUM CHANNEL MODULATION
#362NaK-ATPase-Derived Peptide SRC Inhibitors and Ouabain Antagonists and Uses Thereof
#363METHODS OF TREATING HEMORHEOLOGIC ABNORMALITIES IN MAMMALS
#364Method for treating systemic bacterial, fungal and protozoan infection
#365MYCOTOXIN-REDUCING COMPOSITION
#366Means and Methods for Influencing Electrical Activity of Cells
#367THERAPEUTIC COMPOSITIONS
#368Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
#369Method and pharmacological composition for the diagnosis and treatment of male
#370Oligopeptidic compounds and uses thereof
#371Cosmetic treatment system and methods
#372Cathepsin L mediated diseases and associated methods and products
#373Dynamin mediated diseases and associated methods and products
#374COMPOSITIONS AND METHODS FOR TREATING PANCREATIC INSUFFICIENCY
#375Cosmetic Methods And Compositions For Repairing Human Skin
#376INHIBITION OF NEURONAL DAMAGE
#377Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
#378Na+K+-ATPase-specific peptide inhibitors/activators of SRC and SRC family kinases
#379TARGETED BIOCIDES
#380Methods and compositions for treating nephrogenic diabetes and insipidus
#381Antibody formulations and methods of making same
#382PHENOTYPIC REVERSION OF PANCREATIC CARCINOMA CELLS
#383Polypeptide targeting to mitochondria
#384METHOD OF TREATING PULMONARY EDEMA OR PULMONARY INFLAMMATION
#385Anti-p55 TNF receptor antibody
#386TISSUE-NONSPECIFIC ALKALINE PHOSPHATASE (TNAP) ACTIVATORS AND USES THEREOF
#387COSMETIC METHODS AND COMPOSITIONS FOR REPAIRING HUMAN SKIN
#388SERCA2 THERAPEUTIC COMPOSITIONS AND METHODS OF USE
#389AGENTS FOR PROPHYLAXIS OR TREATMENT OF NEUROLOGICAL RELATED DISEASES AND CONDITIONS
#390METHODS AND RELATED SYSTEMS AND FORMULATIONS TO NORMALIZE AND IMPROVE HUMAN BODY CHEMISTRY AND HEALING ABILITY
#391TARGETED DELIVERY AND EXPRESSION OF PROCOAGULANT HEMOSTATIC ACTIVITY
#392TARGETED ENZYMES
#393RHO Family Antagonists and Their Use to Block Inhibition of Neurite Outgrowth
#394Compositions for treatment of gastro-esophageal reflux disorders
#395Local Gene Therapy with an Eluting Stent for Vascular Injury
#396Regulation of cell migration and adhesion
#397Focal calcium channel modulation
#398Novel biphasic delivery system for a pharmaceutical or nutraceutical composition and method of administration
#399Method of screening for agents that modulate Tysnd1 level or activity in a cell.
#400Phenotypic reversion of pancreatic carcinoma cells
#401TREATMENT OF INFECTIONS AND OTHER DISORDERS
#402Cosmetic treatment system and methods
#403Use of β-1,3 (4)-endoglucanohydrolase, β-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
#404Dynamin mediated diseases and associated methods and products
#405Process for the manufacture and use of pancreatin micropellet cores
#406Targeted biocides
#407Composition and method of treating mastitis
#408RhoB as a suppressor of cancer cell growth, cell transformation, and metastasis
#409TNF receptor action modulation
#410Proteic binding partners of TCTP and methods of modulating tumor reversion or cell apoptosis
#411Phenotypic reversion of pancreatic carcinoma cells
#412Elastin prevents occlusion of body vessels by vascular smooth muscle cells
#413Use of beta-1,3 (4)-endoglucanohydrolase, beta-1,3 (4) glucan, diatomaceous earth, mineral clay and glucomannan to augment immune function
#414Regulation of cell migration and adhesion
#415Regulation of matrix metalloproteinases by PSP94 family members
#416Mutant OPAA enzyme with increased catalytic efficiency on GP
#417Microtubule organizing center (MTOC)-inactivating peptides
#418Compositions and methods for modulating coagulation